CN105968067A - Valinomycin B, preparation method and medical purpose thereof - Google Patents

Valinomycin B, preparation method and medical purpose thereof Download PDF

Info

Publication number
CN105968067A
CN105968067A CN201510908937.3A CN201510908937A CN105968067A CN 105968067 A CN105968067 A CN 105968067A CN 201510908937 A CN201510908937 A CN 201510908937A CN 105968067 A CN105968067 A CN 105968067A
Authority
CN
China
Prior art keywords
liquid
valinomycins
culture
streptomyces
valinomycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201510908937.3A
Other languages
Chinese (zh)
Other versions
CN105968067B (en
Inventor
张治针
叶雪威
连晓媛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang University ZJU
Original Assignee
Zhejiang University ZJU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang University ZJU filed Critical Zhejiang University ZJU
Priority to CN201510908937.3A priority Critical patent/CN105968067B/en
Publication of CN105968067A publication Critical patent/CN105968067A/en
Application granted granted Critical
Publication of CN105968067B publication Critical patent/CN105968067B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/14—Nitrogen or oxygen as hetero atom and at least one other diverse hetero ring atom in the same ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a compound valinomycin B having glioma activity resistance, provides an active substance producing strain streptomyces parvus separated and cultured from sea mud, and the active substance valinomycin B can be prepared. The streptomyces parvus is preserved in the China Center for Type Culture Collection and named as P11-23B (Streptomyces parvus P11-23B) with a preservation number of CCTCC NO: M 2015675 on Nov, 12th, 2015. The valinomycin B has features of obviously inhibiting multiplication of various kinds of glioma cells, obviously inhibiting glioma cell cycle at G0/G1 phase, and reducing the protein level expression of several key enzymes with different metabolism approaches of glioma cells, and has unique anti-tumor effect. The valinomycin B can be used for preparing medicines for treating glioma. The chemical structural formula of the valinomycin B is as shown in the specification.

Description

Valinomycins B and preparation and medical usage
Technical field
The invention belongs to field of medicaments, relate to from marine actinomycete streptomyces parvus (Streptomyces parvulus P11- Method and this compound of preparing active compound for anti tumor valinomycins B (Valinomycin B) in 23B) are treated in preparation Application in terms of cerebral glioma medicine.
Background technology
Cerebral glioma is the cerebral tumor most common and the most pernicious in brainpan, accounts for the 70% of all malignant brain tumors.The world defends Raw tissue statistical data shows: glioblastoma is the 2nd cause of death of less than 34 years old tumor patient, is 35～54 years old patient The 3rd cause of death, the health of the serious harm mankind and life.Glioma is special due to location, and operating difficulty is big And be not easy tumor complete resection, so radiotherapy and medicine are particularly important to the treatment of glioma., current anticol matter Tumor medicine famine, temozolomide is the most selectable medicine being individually used for Treatment for Glioma.And, including for not azoles Amine, at the offer limited effectiveness of interior existing treatment glioma medicine, has wretched insufficiency more, and outstanding behaviours is: (1) mostly is chemicals, poison Side effect is big；(2) the tumor cell serious drug resistance to medicine；(3) blood brain barrier hinders in medicine arrives brain and plays its treatment Effect.Therefore, need to overcome disadvantages described above, better efficacy, the novel anticol matter that safety is higher and mechanism of action is unique clinically Tumor medicine.
Numerous studies prove: excessive glycolysis (Glycolysis), vigorous glutamine decompose And lipid synthesis (Lipogenesis) is that glioma cell metabolism is different from the prominent of normal cell metabolism (Glutaminolysis) Go out feature.It is high by the special dependence of glioma cell in glycolysis link that glioma cell absorbs a large amount of glucose from microenvironment The multiple key enzymes expressed include Hexokinase 2 (HK2), phosphofructokinase/fructose 2,6-diphosphatase (PFKFB3), acetone Acid kinase M2 (PKM2) and lactic acid dehydrogenase 5 (LDH5) etc. participate in producing a large amount of intermediate products and end-product lactic acid jointly, these Intermediate product is the initiation material of tumor cell synthesising biological macromole, and Lactic Acid Secretion can suppress immunity of organism thin to extracellular Born of the same parents' Scavenging activity to tumor cell, can promote that tumor cell spreads, and the glycolysis key enzyme HK2 of high expressed also can improve tumor Cell is to radiotherapy and the resistance of temozolomide's chemotherapy.Meanwhile, the vigorous glutamine decomposition that transglutaminase (GLS) is leading, There is provided substantial amounts of nitrogen source for the synthesis of biomolecule, and the leading active lipid of the fatty acid synthetase of high expressed (FASN) is closed Become to be conducive to the generation of cell membrane.It can be appreciated that tumor cell height utilizes its metabolic intermediate synthesising biological to divide greatly just Sub-DNA, RNA, protein and biomembranous ability promote it the most unrestrictedly to breed, the pass of modulate tumor metabolism difference link Key enzyme can effectively suppress the propagation of tumor cell.Therefore, the multiple target effect of targeting glioma metabolism difference link key enzyme Medicine is likely to be of more preferable antitumor curative effect.Valinomycins B (Valinomycin B) is from marine bacteria streptomyces parvus P11- The noval chemical compound of isolated in 23B (Streptomyces parvulus P11-23B), this compound is to multiple different colloids The propagation of oncocyte has significant inhibitory action, can obviously reduce glioma cell glycolysis, glutamine decomposition and lipid The protein expression level of several key enzymes in route of synthesis, has the Anticancer Effect and Mechanism of uniqueness, and therefore, valinomycins B exists Prepare anticol matter tumor medicine aspect to have a good application prospect.
Summary of the invention
It is an object of the present invention to provide a kind of compound valinomycins B with anticol matter tumor activity (Valinomycin B, compound 1), described valinomycins B is a noval chemical compound, and its chemical structural formula is:
It is a further object to provide the preparation method of valinomycins B (Valinomycin B), by following step Rapid realization:
(1) preparation of streptomyces parvus Streptomyces parvulus P11-23B zymocyte liquid
Take the colony inoculation of streptomycete Streptomyces parvulus P11-23B to containing a certain amount of liquid spawn In the big conical flask of culture medium, after the culture fluid containing P11-23B strain at ambient temperature shaken cultivation certain time To prepare strain liquid.Finally strain liquid is proceeded to the big conical flask containing a certain amount of liquid fermentation medium, at room temperature bar Under part after oscillation and fermentation cultivation certain time, obtain the zymocyte liquid with the P11-23B of anti-tumor activity.
Described liquid spawn culture medium and liquid fermentation medium are liquid Gao Shi culture medium；Described consumption is 100-200mL；Described big triangle culture bottle is 250 or 500mL；Described incubated at room temperature temperature is 20～30 DEG C；Described shake The rotating speed swung is 160-180rpm；Described incubation time is 5～15 days.
(2) extraction separation and purification of valinomycins B (Valinomycin B)
The zymocyte liquid of bacterial strain P11-23B is extracted with ethyl acetate and obtains acetic acid ethyl ester extract, acetic acid ethyl ester extract By octadecylsilane chemically bonded silica (ODS) column chromatography for separation, respectively with 70% and 100% methanol-eluted fractions, the methanol of 100% After eluent merging, the residue HPLC through being concentrated under reduced pressure to give separates, and obtains pure compound valinomycins B (Valinomycin B)。
The ODS consumption of described column chromatography and the sample size ratio of upper amount are 40～60g:1.0g；Described efficient liquid phase is divided From condition it is: Agilent 1260 high performance liquid chromatograph, Agilent 1260DAD detector, Agilent Zorbax SB- C18Chromatographic column (250 × 9.4mm, 5 μm), 100% methanol is flowing phase, column temperature 26 DEG C, detects wavelength 210nm, and flow velocity is 1.0mL/min。
(3) Structural Identification of valinomycins B (Valinomycin B)
The structure of valinomycins B (Valinomycin B) is the NMR spectra of a peacekeeping two dimension according to them, high-resolution The method such as mass spectrometric data and chemical degradation is identified.
Third object of the present invention is to provide a kind of streptomyces parvus P11-23B, and described bacterial strain is preserved in Chinese Typical Representative Culture collection center, Classification And Nomenclature is streptomyces parvus P11-23B (Streptomyces parvulus P11-23B), preservation Numbering CCTCC NO:M 2015675, preservation day 2015.11.12, preservation address: Wuhan, China.
Fourth object of the present invention is to provide the preparation method of described streptomyces parvus P11-23B, is a kind of from sea mud Middle separation has the method for the bacterial strain P11-23B of anticol matter tumor activity, is obtained by following steps separation and Culture:
(1) separation and Culture of streptomyces parvus (Streptomyces parvulus P11-23B)
Take air dried sea mud sea water and be diluted to certain concentration, take a certain amount of sample diluting liquid and evenly spread to In culture dish containing solid medium, after cultivating certain time at ambient temperature, different bacterium colonies is transferred to separately respectively One, containing in the culture dish of solid medium, continues to cultivate certain time at ambient temperature.Finally by well-grown single It is standby that bacterium colony (P11-23B) is inoculated into the slant medium rearmounted 4 DEG C of Refrigerator stores of cultivation.
Described sea mud and sea water are to obtain from Zhoushan Of Zhejiang Province Area of The East China Sea；The concentration of described sample diluting liquid is 1 × 10-6～1 × 10-4g/mL；The sampling amount of described sample diluting liquid is 100～300 μ L；Solid training contained by described culture dish Foster base is Gao Shi agar (Gause ' s agar) culture medium or other solid medium；Described slant medium is Gao Shi agar Culture medium or other solid slant culture base；Described incubated at room temperature temperature is 20～30 DEG C；Described incubation time is 7～15 My god.
(2) strain identification of streptomyces parvus (Streptomyces parvulus P11-23B)
The 16S rDNA sequence analysis that the bacterial strain that above-mentioned steps (1) separation and Culture is obtained commonly uses with current laboratory Method identifies the kind of bacterial strain P11-23B, is defined as streptomyces parvus, and Classification And Nomenclature is Streptomyces parvulus P11- 23B, by China typical culture collection center-center, Wuhan preservation, deposit number CCTCC NO:M 2015675.
5th purpose of the present invention is to provide valinomycins B application in preparation treatment cerebral glioma medicine.Described Valinomycins B can significantly inhibit the propagation of multiple glioma cell, the retardance glioma cell cycle, in the G0/G1 phase, reduces glue Matter oncocyte glycolysis, glutamine decompose and the protein expression of multiple key enzymes in lipid route of synthesis, have uniqueness Function of tumor mechanism.
Described medicine is that valinomycins B activity composition is independent, or valinomycins B and other medicines or with effective ingredient one Rise, the medicine formed with pharmaceutically acceptable carrier.The dosage form of described medicine is: liquid preparation, solid preparation, capsule Preparation, slow releasing preparation, nanometer formulation.
The present invention from sea mud separation and Culture to active substance producing strains streptomyces parvus Streptomyces parvulus P11-23B, and therefrom it is found that new active substance valinomycins B (Valinomycin B).Valinomycins B significantly inhibits many Plant brain glioblastoma cell propagation, hence it is evident that the retardance glioma cell cycle is in G0/G1Phase, reduce glioma cell different metabolic approach The protein expression of multiple key enzymes, there is the Anticancer Effect and Mechanism of uniqueness.Therefore, valinomycins B is in preparation treatment Cerebral glioma medicine aspect has application prospect.
Accompanying drawing explanation
Fig. 1 is the bacterium colony figure of streptomyces parvus Streptomyces parvulus P11-23B.
Fig. 2-6 is the hydrogen spectrum of valinomycins B (Valinomycin B).
Fig. 7-11 is the carbon spectrum of valinomycins B (Valinomycin B).
Figure 12 is valinomycins B (Valinomycin B)1H-1H COSY composes.
Figure 13-16 is the hsqc spectrum of valinomycins B (Valinomycin B).
Figure 17-23 is the HMBC spectrum of valinomycins B (Valinomycin B).
Figure 24 is the high resolution mass spectrum of valinomycins B (Valinomycin B).
Figure 25 is the valinomycins B (Valinomycin B) inhibitory action to glioma.
Figure 26 is that valinomycins B (Valinomycin B) retardance glioma U87-MG cell cycle is in the G0/G1 phase.
Figure 27 is that valinomycins B (Valinomycin B) retardance glioma U251 cell cycle is in the G0/G1 phase.
Figure 28 is that valinomycins B (Valinomycin B) reduces glioma U87-MG cell different metabolic pathway key enzyme Protein expression level (CON:U87-MG cell controls group；1: valinomycins B process group；DMSO: dimethyl sulfoxide solvent compares Group；HK2: hexokinase: PFKFB3: phosphofructokinase/fructose 2,6-diphosphatase；PKM2: pyruvate kinase M2；GLS: paddy Transglutaminase；FASN: fatty acid synthetase；β-ACTIN: beta-actin, internal reference).
Detailed description of the invention
Below in conjunction with drawings and Examples, the present invention is described in further detail.But, the invention is not restricted to these real Execute example.
The separation and Culture of embodiment 1. streptomyces parvus P11-23B (Streptomyces parvulus P11-23B)
Taking air dried sea mud 1 gram sea water and being diluted to concentration is 1 × 10-6The sample diluting liquid of g/mL, takes 200 μ L's Sample diluting liquid evenly spreads in the culture dish containing Gao Shi agar (Gause ' s agar) solid medium, 28 DEG C of conditions After lower cultivation 7 days, different bacterium colonies is transferred to respectively in another culture dish containing Gao Shi Solid agar culture, at 28 DEG C Under the conditions of continue cultivate 7 days.Finally well-grown single bacterium colony (P11-23B) is inoculated into the training of Gao Shi agar slant culture-medium Support rearmounted 4 DEG C of Refrigerator stores standby.
The strain identification of embodiment 2. streptomyces parvus P11-23B (Streptomyces parvulus P11-23B)
16S rDNA sequence analysis method is used to identify the kind of obtained bacterial strain P11-23B.
2.1 experiment reagents and instrument
PCR reagent: EX Taq enzyme (TaKaRa), dNTP (TaKaRa), primer (Invitrogen synthesis), primer sequence It is: TACGGYTACCTTGTTACGACTT and AGAGTTTGATCMTGGCTCAG；
Marker:DL500
Experimental apparatus: centrifuge, electrophresis apparatus, PCR instrument, ABI 3730XL sequenator.
2.2 experimental procedure
Bacterial genomes DNA extracts；
Electrophoresis detection
PCR expands
A.PCR reaction system
B.PCR reaction condition
10 DEG C of ∞,
C. electrophoresis detection,
D. order-checking: cut glue purification order-checking,
E. analysis result: splicing sequence.
2.3 experimental result
Spliced sequence is:
AACCACTTCGGTGGGGATTAGTGGCGAACGGGTGAGTAACACGTGGGCAATCTGCCCTGCACTCTGGGACAAGCCCT GGAAACGGGGTCTAATACCGGATACTGACCTTCACGGGCATCTGTGAAGGTCGAAAGCTCCGGCGGTGCAGGATGAG CCCGCGGCCTATCAGCTTGTTGGTGAGGTAATGGCTCACCAAGGCGACGACGGGTAGCCGGCCTGAGAGGGCGACCG GCCACACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGAAAGCC TGATGCAGCGACGCCGCGTGAGGGATGACGGCCTTCGGGTTGTAAACCTCTTTCAGCAGGGAAGAAGCGAAAGTGAC GGTACCTGCAGAAGAAGCGCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGCGCAAGCGTTGTCCGGAA TTATTGGGCGTAAAGAGCTCGTAGGCGGCTTGTCACGTCGGTTGTGAAAGCCCGGGGCTTAACCCCGGGTCTGCAGT CGATACGGGCAGGCTAGAGTTCGGTAGGGGAGATCGGAATTCCTGGTGTAGCGGTGAAATGCGCAGATATCAGGAGG AACACCGGTGGCGAAGGCGGATCTCTGGGCCGATACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAG ATACCCTGGTAGTCCACGCCGTAAACGGTGGGCACTAGGTGTGGGCAACATTCCACGTTGTCCGTGCCGCAGCTAAC GCATTAAGTGCCCCGCCTGGGGAGTACGGCCGCAAGGCTAAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGC GGAGCATGTGGCTTAATTCGACGCAACGCGAAGAACCTTACCAAGGCTTGACATACACCGGAAACGTCCAGAGATGG GCGCCCCCTTGTGGTCGGTGTACAGGTGGTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCG CAACGAGCGCAACCCTTGTCCCGTGTTGCCAGCAGGCCCTTGTGGTGCTGGGGACTCACGGGAGACCGCCGGGGTCA ACTCGGAGGAAGGTGGGGACGACGTCAAGTCATCATGCCCCTTATGTCTTGGGCTGCACACGTGCTACAATGGCCGG TACAATGAGCTGCGATACCGCAAGGTGGAGCGAATCTCAAAAAGCCGGTCTCAGTTCGGATTGGGGTCTGCAACTCG ACCCCATGAAGTCGGAGTCGCTAGTAATCGCAGATCAGCATTGCTGCGGTGAATACGTTCCCGGGCCTTGTACACAC CGCCCGTCACGTCACGAAAGTCGGTAACACCCGAAGCCGGTGGCCTCAACCC。
16S rDNA sequence achieved above compares with the NCBI GenBank data base of America NI H, and its result shows: bacterium The 16S of the Streptomyces parvulus strain PFS10 in the 16S rDNA sequence of strain P11-23B and GenBank storehouse RDNA sequence has the similarity (accession number: KJ789323.1) of 99%.Therefore, the marine bacteria strain P11-23B that the present invention is obtained It is set to streptomyces parvus P11-23B (Streptomyces parvulus P11-23B) (accompanying drawing 1).Streptomyces parvus P11-23B (Streptomyces parvulus P11-23B) bacterial strain, by China typical culture collection center-center, Wuhan preservation, is protected Hide numbering CCTCC NO:M 2015675.
The preparation of embodiment 3. streptomyces parvus P11-23B (Streptomyces parvulus P11-23B) zymocyte liquid
The colony inoculation taking streptomycete Streptomyces parvulus P11-23B is trained to containing 200mL liquid Gao Shi Support in the 500mL conical flask of base, the culture fluid containing P11-23B strain is rotated under the conditions of 28 DEG C (180rpm) shaking training Strain liquid is obtained after supporting 7 days.5mL strain liquid is proceeded in the 500mL conical flask containing 200mL liquid Gao Shi culture medium, Rotate (180rpm) shaking under the conditions of 28 DEG C to cultivate 7 days, obtain the zymocyte liquid with the P11-23B of anti-tumor activity.
The extraction separation and purification of embodiment 4. valinomycins B (Valinomycin B)
The zymocyte liquid (50.0 liters) that Example 3 obtains is extracted with ethyl acetate and obtains acetic acid ethyl ester extract (7.56 Gram), acetic acid ethyl ester extract octadecylsilane chemically bonded silica (ODS, 500 grams) column chromatography for separation, respectively with 2000mL's The methanol-eluted fractions of 70% and 100%, after the meoh eluate merging of 100%, the residue (1.38 grams) through being concentrated under reduced pressure to give is used HPLC separates (instrument: Agilent 1260；Chromatographic column: Agilent Zorbax SB-C18, 250 × 9.4mm, 5 μm；Flowing phase: 100% methanol；Column temperature: 26 DEG C；Detection wavelength: 210nm；Flow velocity: 1.0mL/min), obtain valinomycins B (156mg, tR 18.34min)。
Valinomycins B is colourless powder；Molecular formula C53H88N6O18；[α]D 25+36.8.7(c 0.36,MeOH)；IR(KBr) 2967,2936,2873,1743,1655,1193,1094,1027mm；High resolution mass spectrum (HRESIMS) is m/z [M-H]- 1095.6051 (value of calculation C53H87N6O181095.6077).Chiral aminoacid post and gas chromatographic analysis, and with standard substance pair According to, the acid hydrolysis products of valinomycins B be accredited as D-Val (D-Val), Valine (L-Val), Pfansteihl (L-Lac), D-Alpha-hydroxy isovaleric acid (D-Hiv), D-alpha-hydroxybutyric acid (D-Hbu).
According to valinomycins B's1H spectrum (accompanying drawing 2-6),13C spectrum (accompanying drawing 7-11),1H-1H COSY composes (accompanying drawing 12), HSQC Spectrum (accompanying drawing 13-16), HMBC spectrum (accompanying drawing 17-23), high resolution mass spectrum figure (accompanying drawing 24) and chemical degradation, the knot of valinomycins B Structure is accredited as noval chemical compound, its13C and1H NMR signal ownership is shown in Table one.
Table one, the carbon of valinomycins B and hydrogen signal ownership (in CDCl3)
The activity research of embodiment 5. valinomycins B
5.1. the effect of valinomycins B suppression tumor cell proliferation
Rat brain glioma C6 cell and human glioma U251 cell DMEM and 10%FBS culture medium at 37 DEG C and The incubator of 5% carbon dioxide is cultivated, and human glioma U87-MG and SHG-44 cell respectively by MEM culture medium and RPMI-1640 culture medium is cultivated in the incubator of 37 DEG C and 5% carbon dioxide, through the cell of three cultures for the present invention Experimentation.
Measuring tumor cell survival by Sulforhodamine B (SRB) method, amycin (Doxorubicin) is used for positive drug Comparison.Cell is inoculated in 96 orifice plates, adds the valinomycins B of variable concentrations after adherent 24h.Contaminate with SRB after drug treating 72h Color, measures the absorbing light angle value at 515nm, the survival rate of detection tumor cell by microplate reader, calculates valinomycins B and suppress colloid The IC of tumor cell proliferation50Value.Test result indicate that: valinomycins B significantly inhibits the propagation of glioma cell, its IC50Value is respectively For 0.25-0.41 μM (table two, accompanying drawing 25).
Effect (the IC of table two, valinomycins B suppression glioma50:μM)
5.2. the valinomycins B retardance glioma cell cycle is in G0/G1Phase
After dyeing with propidium iodide (PI) DNA, flow cytometry analysis valinomycins B is thin to glioma U87-MG and U251 The impact in intracellular growth cycle.By glioma U87-MG and U251 cell respectively with valinomycins B (0.8 μM) process 12h, 24h, 48h or and 72h after, collect cell and with frost 70% ethanol mix after under the conditions of 4 DEG C overnight.Mixed liquor after overnight The cells rinsed with PBS of (1900rpm, 7 minutes) isolated twice by centrifugation.Cell is dispersed in again containing RNase A's In PBS, hatch 30 minutes at 37 DEG C, finally dye 30 minutes at 4 DEG C of dark with propidium iodide (PI).Use FACScan streaming The Cytometric Analysis valinomycins B change to U87-MG and U251 cell cycle.Experimental result shows: (1) compares with matched group, After valinomycins B (0.8 μM) processes glioma U87-MG cell 12h, 24h and 48h, the G of cell cycle0/G1Phase cell proportion divides Do not add 40.92%, 32.54% and 31.30% (table three, accompanying drawing 26).
Table three, the valinomycins B impact on glioma U87-MG cell cycle
(2) comparing with matched group, valinomycins B (0.8 μM) processes glioma U87-MG cell 12h, 24h, 48h and 72h After, the G of cell cycle0/G1Phase cell proportion adds 40.92%, 32.54% and 31.30% (table four, accompanying drawing 27) respectively.
Table four, the valinomycins B impact on glioma U251 cell cycle
These results suggest that, valinomycins B is blocked in the glioma cell cycle in G0/G1Phase.
5.3. the valinomycins B impact on glioma cell different metabolic pathway key enzyme
The preparation of protein sample: people glioma U87-MG cell MEM and 10%FBS culture medium are at 37 DEG C and 5% dioxy Changing in the incubator of carbon and cultivate, the cell through three cultures is used for the experimentation of the present invention.Cell (1.5 × 107) inoculation In the culture dish of 10 centimetres, after addition valinomycins B (5.0 μMs or 10.0 μMs) co-cultures 48 hours after adherent 24h, first use ice Cold PBS is washed twice, and rear ice-cold lysis buffer (200 μ L) cracks 15 minutes.Lysate is through 4 DEG C of low-temperature and high-speeds (11200rpm) centrifugal, supernatant is protein sample.
The mensuration of protein content: use the protein content of BCA each protein sample of kit measurement.By seminal plasma fructose detection kit A and B is made into working reagent liquid with 50:1 ratio, with bovine serum albumin (BSA), standard substance BCA dilution is made into variable concentrations BCA standard solution.30 points are hatched at 37 DEG C after taking 10 μ L standard solution or protein sample liquid and the mixing of 200 μ L working reagent liquid Clock. artemia hatching solution microplate reader measures trap at 562nm wavelength.With BCA amount as abscissa, trap is that vertical coordinate draws standard Curve, calculates regression equation.Protein content from regression equation calculation each protein sample liquid.
Western Blotting: each sample containing equal protein (15 μ g) is with 10% dodecyl sodium sulfate polyacrylamide Amine gel electrophoresis (SDS-PAGE) separates, and is forwarded to by gel electrophoresis protein graphical spectrum on polyvinylidene fluoride film (PVDF), and pvdf membrane is used 5% is also had to go the 0.1%TBST of fat milk at room temperature to close 2 hours.Pvdf membrane after closing first with HK2, PFKFB3, The one of PKM2, FASN and GLS enzyme resists 4 DEG C of overnight incubation, washes film with TBST；Resist in incubated at room 2 little afterwards with the two of HRP labelling Time.After TBST washes film three times, detect immunoreactivity with enhanced chemiluminescence reagent, then develop, washing, fixing, washing, dry in the air Dry, observation experiment result.Compare using beta-actin (β-ACTIN) as internal reference.
Test result indicate that: compare, valinomycins B with negative control group (not having the U87-MG cell of drug treating) (10.0 μMs) significantly reduce the protein level table of key enzyme HK2, PFKFB3, FASN and the GLS of tumor cell different metabolic approach Reach (accompanying drawing 28).This result is pointed out, and valinomycins B may be by affecting glioma glycolysis, glutamine decomposition and lipid Synthesis key enzyme and produce its anti-tumor activity, have uniqueness Mutiple Targets Anticancer Effect and Mechanism.
In sum, present invention demonstrates that valinomycins B significantly inhibits the propagation of multiple glioma cell, blocks tumor cells Cycle is in G0/G1Phase, the protein expression of multiple key enzymes during significantly reducing glioma cell different metabolic, have solely Special Anticancer Effect and Mechanism, so, valinomycins B before the related drugs prepared has application in terms for the treatment of cerebral glioma Scape.

Claims (7)

1. anticol matter tumor activity material valinomycins B (Valinomycin B), it is characterised in that there is following chemistry knot Structure formula:
2. a streptomyces parvus P11-23B, it is characterised in that described streptomyces parvus bacterial strain is preserved in Chinese Typical Representative culture and protects Center, Tibetan, Classification And Nomenclature is streptomyces parvus P11-23B (Streptomyces parvulus P11-23B), deposit number CCTCC NO:M 2015675, preservation day 2015.11.12, preservation address: Wuhan, China.
3. the preparation method of the anticol matter tumor activity material valinomycins B described in claim 1, it is characterised in that by following Step realizes:
(1) preparation of streptomyces parvus P11-23B (Streptomyces parvulus P11-23B) zymocyte liquid:
Take the colony inoculation of streptomyces parvus P11-23B in the big conical flask containing a certain amount of liquid spawn culture medium, will To prepare strain liquid after culture fluid containing P11-23B strain shaken cultivation certain time at ambient temperature, finally by strain Liquid proceeds to the big conical flask containing a certain amount of liquid fermentation medium, oscillation and fermentation cultivation certain time at ambient temperature After, obtain the zymocyte liquid with the P11-23B of anti-tumor activity；
Described liquid spawn culture medium and liquid fermentation medium are liquid Gao Shi culture medium；Described consumption is 100- 200mL；Described big triangle culture bottle is 250 or 500mL；Described incubated at room temperature temperature is 20～30 DEG C；Described vibration Rotating speed be 160-180rpm；Described incubation time is 5～15 days；
(2) extraction separation and purification of valinomycins B
The zymocyte liquid of bacterial strain P11-23B is extracted with ethyl acetate and obtains acetic acid ethyl ester extract, and acetic acid ethyl ester extract is with ten Eight alkyl silane bonded silica gel (ODS) column chromatography for separation, respectively with 70% and 100% methanol-eluted fractions, the methanol-eluted fractions of 100% After liquid merging, the residue HPLC through being concentrated under reduced pressure to give separates, and obtains pure compound valinomycins B；
The octadecylsilane chemically bonded silica consumption of described column chromatography and the sample size ratio of upper amount are 40～60g:1.0g；Described High-efficient liquid phase separation be: Agilent 1260 high performance liquid chromatograph, Agilent 1260DAD detector, Agilent Zorbax SB-C18Chromatographic column 250 × 9.4mm, 5 μm, 100% methanol is flowing phase, column temperature 26 DEG C, detects wavelength 210nm, stream Speed is 1.0mL/min；
(3) Structural Identification of valinomycins B:
NMR spectra, high resolution mass spectrum data and chemical degradation method according to a peacekeeping two dimension identifies the knot of valinomycins B Structure.
4. the preparation method of the streptomyces parvus described in claim 2, it is characterised in that obtained by following steps separation and Culture :
(1) separation and Culture of streptomyces parvus P11-23B:
Take air dried sea mud sea water and be diluted to certain concentration, take a certain amount of sample diluting liquid evenly spread to containing In the culture dish of solid medium, after cultivating certain time at ambient temperature, different bacterium colonies is transferred to another respectively and contains Have in the culture dish of solid medium, continue at ambient temperature to cultivate certain time, finally single bacterium colony (P11-23B) is connect Plant the slant medium rearmounted 4 DEG C of Refrigerator stores of cultivation standby；
Described sea mud and sea water are to obtain from Zhoushan Of Zhejiang Province Area of The East China Sea；The concentration of described sample diluting liquid is 1 × 10-6~ 1×10-4g/mL；The sampling amount of described sample diluting liquid is 100～300 μ L；Solid medium contained by described culture dish is Gao Shi agar (Gause ' s agar) culture medium or other solid medium；Described slant medium is Gao Shi agar culture medium Or other solid slant culture base；Described incubated at room temperature temperature is 20～30 DEG C；Described incubation time is 7～15 days；
(2) strain identification of streptomyces parvus P11-23B:
The 16S rDNA sequence analysis method that the bacterial strain that above-mentioned steps (1) separation and Culture is obtained commonly uses with current laboratory Identifying the kind of bacterial strain P11-23B, be defined as streptomyces parvus, Classification And Nomenclature is Streptomyces parvulus P11-23B, By China typical culture collection center-center, Wuhan preservation, deposit number CCTCC NO:M2015675.
The active substance valinomycins B the most according to claim 1 application in preparation treatment cerebral glioma medicine.
Application the most according to claim 5, it is characterised in that described medicine is that valinomycins B activity composition is independent, or with Other medicines or together with effective ingredient, the medicine formed with pharmaceutically acceptable carrier.
7. according to the application described in claim 5 or 6, it is characterised in that the dosage form of described medicine is liquid preparation, solid Preparation, capsule preparations, slow releasing preparation, nanometer formulation.
CN201510908937.3A 2015-12-10 2015-12-10 Valinomycins B and preparation and medical usage Active CN105968067B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510908937.3A CN105968067B (en) 2015-12-10 2015-12-10 Valinomycins B and preparation and medical usage

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510908937.3A CN105968067B (en) 2015-12-10 2015-12-10 Valinomycins B and preparation and medical usage

Publications (2)

Publication Number Publication Date
CN105968067A true CN105968067A (en) 2016-09-28
CN105968067B CN105968067B (en) 2018-04-20

Family

ID=56988193

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510908937.3A Active CN105968067B (en) 2015-12-10 2015-12-10 Valinomycins B and preparation and medical usage

Country Status (1)

Country Link
CN (1) CN105968067B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112159777A (en) * 2020-09-30 2021-01-01 浙江工业大学 Cyclopeptide antibiotic valinomycin high-yield strain and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103665108A (en) * 2013-10-26 2014-03-26 中国海洋大学 Preparation methods and application of streptomyces parvulus OUCMDZ-2554 bacterial strain and product actinomycin D thereof
CN103695358B (en) * 2013-12-24 2015-08-26 扬州大学 The one small streptomycete in strain ocean and the application in quorum sensing suppression thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103665108A (en) * 2013-10-26 2014-03-26 中国海洋大学 Preparation methods and application of streptomyces parvulus OUCMDZ-2554 bacterial strain and product actinomycin D thereof
CN103695358B (en) * 2013-12-24 2015-08-26 扬州大学 The one small streptomycete in strain ocean and the application in quorum sensing suppression thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
XUEWEI YE ET AL: "Antiproliferative cyclodepsipeptides from the marine actinomycete Streptomyces sp. P11-23B downregulating the tumor metabolic enzymes of glycolysis, glutaminolysis, and lipogenesis", 《PHYTOCHEMISTRY》 *
梁英等: "基于肿瘤代谢靶标的抗脑胶质瘤海洋天然活性物质的发现和研究", 《第十二届海洋药物学术年会会刊》 *
沈会芳等: "近海海泥链霉菌的分离方法", 《中国生物防治》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112159777A (en) * 2020-09-30 2021-01-01 浙江工业大学 Cyclopeptide antibiotic valinomycin high-yield strain and application thereof
CN112159777B (en) * 2020-09-30 2021-11-09 浙江工业大学 Cyclopeptide antibiotic valinomycin high-yield strain and application thereof

Also Published As

Publication number Publication date
CN105968067B (en) 2018-04-20

Similar Documents

Publication Publication Date Title
Ye et al. Antiproliferative cyclodepsipeptides from the marine actinomycete Streptomyces sp. P11-23B downregulating the tumor metabolic enzymes of glycolysis, glutaminolysis, and lipogenesis
Mitova et al. Cyclic peptides from a Ruegeria strain of bacteria associated with the sponge Suberites domuncula
Nikapitiya Bioactive secondary metabolites from marine microbes for drug discovery
CN107353274B (en) Selenolonic acid I from penicillium oxalicum and application thereof in preparation of human esophageal cancer resistant medicine
Natarajan et al. Characterization of the fungicidal activity of Calothrix elenkinii using chemical methods and microscopy
CN107298672B (en) Application of seclenic acid I derived from penicillium oxalicum in preparation of anti-human colon cancer drugs
CN109970538A (en) The Dimeric sesquiterpene compound in a kind of marine fungi source and preparation method thereof and application in preparing anti-inflammatory drugs
CN105670968B (en) A kind of marine natural anticol matter tumor activity substance and preparation and use
CN108315264A (en) A kind of polyketide in sea paint endogenetic fungus source and its application in preparing anti-inflammatory drug
CN105504021B (en) A kind of Peptaibol antibacterial peptide compounds and its preparation method and application
CN108640968B (en) Mixed-source terpenoid and application thereof in preparation of anti-inflammatory drugs
CN107298669B (en) Selenolonic acid I from penicillium oxalicum and application of medicine for resisting human oral epidermoid carcinoma
CN105968067B (en) Valinomycins B and preparation and medical usage
CN106008485A (en) Medicinal composition of glimepiride, and application thereof in biomedicines
CN111646993B (en) Marine anti-glioma active substance iso-wall carboline base C, preparation and application thereof
CN105112322B (en) Grey mold quinone A and B and preparation method thereof and medical usage
CN111747955B (en) Marine anti-glioma active substance isobaric carboline alkali A, preparation and application thereof
CN109422651B (en) Decalin compound and application thereof
CN112500340B (en) Tetrahydroquinoline alkaloid with anti-prostate cancer activity and preparation method and application thereof
CN108913606A (en) A kind of ocean antimicrobial agent active material and preparation and use
CN107619803A (en) A kind of preparation of the sour and dark yellow strepto- ketone of dark yellow strepto- and its medical usage
CN109134417B (en) Selenolonic acid I from penicillium oxalicum and application of medicine for resisting human cervical cancer
CN106167517B (en) Anticol matter tumor activity substance strepto- depsipeptides P11B and preparation and application
CN102250176B (en) Antitumor antibiotic ancomycin and its derivative
CN110872266B (en) Marine penicillium sesquiterpene lactone antitumor active substance and preparation and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant